Sign inJoin waitlistJoin the waitlist

Arezoo Ghaneie

Fellowship Program Director · Main Line Health System

Credentials: · · · · · ·

History

Main Line Health System Fellowship
Present
Main Line Health System
Present

Hematology and Medical Oncology
Lankenau Medical Center
2001–2004
Internal Medicine
Reading Hospital
1998–2001
Heinrich-Heine-Universität Düsseldorf Medizinische Fakultät
1994–1998

Research

Salvage Fractionated Stereotactic Radiotherapy with or without Chemotherapy and Immunotherapy for Recurrent Glioblastoma Multiforme: A Single Institution Experience
Frontiers in Oncology · 2015 · 28 citations
Bin1 attenuation in breast cancer is correlated to nodal metastasis and reduced survival
Cancer Biology & Therapy · 2007 · First of 8 authors · 23 citations
Glucose-6-Phosphate Dehydrogenase Deficiency-Associated Hemolytic Anemia and Methemoglobinemia in a Patient Treated With Hydroxychloroquine in the Era of COVID-19
Case report · Cureus · 2021 · 9 citations

AM
Alisha Maity
3 papers · 3 as a fellow
Deric Savior
2 papers
JT
Jian Tan
2 papers · 2 as a resident
JH
Julie Hibbs
2 papers · 1 as a fellow
Kah Loh
2 papers · 2 as a fellow
KS
Karthik Shankar
2 papers · 2 as a fellow
OA
Obed Agyei
2 papers · 2 as a fellow
Paul Gilman
2 papers
VZ
Vlasta Zemba-Palko
2 papers
Zonera Ali
2 papers
Aarti Shevade
1 paper
Akshar Kalola
1 paper · 1 as a fellow

Clinical trials

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2032
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2023–2033